Does Texas genomics (TXG) stock deliver strong earnings and revenue surprises?
· 5 analysts have issued 1-year price objectives for 10x Genomics' stock. Their forecasts range from $24.00 to $205.00. On average, they anticipate 10x Genomics' share price to reach $123.17 in the next twelve months. This suggests a possible upside of 158.6% from the stock's current price.
What does TXG-t stand for?
· 10x Genomics (NASDAQ: TXG) is trading ~18% lower in the post-market on Wednesday after the company set its 2022 revenue guidance below Wall Street forecasts despite a strong revenue beat for Q4 ...
Is 10x Genomics's stock a buy or sell?
Find the latest 10x Genomics, Inc. (TXG) stock quote, history, news and other vital information to help you with your stock trading and investing.
Why are airline stocks down today?
Get the latest 10x Genomics, Inc. (TXG) stock news and headlines to help you in your trading and investing decisions.
Will TXG stock go up?
10X Genomics Inc (NASDAQ:TXG) The 7 analysts offering 12-month price forecasts for 10X Genomics Inc have a median target of 115.00, with a high estimate of 150.00 and a low estimate of 85.00. The median estimate represents a +119.09% increase from the last price of 52.49.
Is TXG stock a buy?
The consensus among 3 Wall Street analysts covering (NASDAQ: TXG) stock is to Strong Buy TXG stock.
Is 10x genomics a good investment?
10x Genomics, Inc. (NASDAQ:TXG) delivered a -44.68% return since the beginning of the year, while its 12-month returns are down by -58.22%. The stock closed at $82.41 per share on April 04, 2022. "We also established a position in 10x Genomics (TXG).
Why did 10x stock drop?
10x Genomics (NASDAQ:TXG) stock dropped to a near 3-week low on Wednesday after Goldman Sachs slashed its price target to $85 from $95, but maintained its Neutral rating. The new PT implies 18.9% upside to TXG's last close. Wall Street analysts on average rated TXG Buy, with an average PT of $125.71.
Where is 10x genomics located?
Pleasanton, California10x Genomics, Inc. is an American company incorporated in 2012 that develops and manufactures integrated systems for whole genome sequencing, exome sequencing and single cell transcriptomics. Its headquarters are located in Pleasanton, California.
Is 10x genomics a public company?
10x Genomics announced its initial public offering on September 12, 2019, raising $390M. The company had revenues of $3.32 million in 2015, $27.48 million in 2016, $71.18 million in 2017 and $145 million in 2018.
Is 10x Genomics a buy right now?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for 10x Genomics in the last year. There are currently 2 hold ratings and 3 bu...
How has 10x Genomics' stock price been impacted by COVID-19?
10x Genomics' stock was trading at $60.76 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Sin...
When is 10x Genomics' next earnings date?
10x Genomics is scheduled to release its next quarterly earnings announcement on Wednesday, May 4th 2022. View our earnings forecast for 10x Genom...
How were 10x Genomics' earnings last quarter?
10x Genomics, Inc. (NASDAQ:TXG) announced its earnings results on Tuesday, February, 15th. The company reported ($0.16) earnings per share (EPS) fo...
What guidance has 10x Genomics issued on next quarter's earnings?
10x Genomics issued an update on its FY 2022 earnings guidance on Wednesday, March, 2nd. The company provided EPS guidance of for the period. The c...
What price target have analysts set for TXG?
5 Wall Street analysts have issued 1-year price targets for 10x Genomics' stock. Their forecasts range from $24.00 to $205.00. On average, they ant...
Who are 10x Genomics' key executives?
10x Genomics' management team includes the following people: Dr. Serge Saxonov Ph.D. , Co-Founder, CEO & Director (Age 44, Pay $654.99k) Dr. Ben...
What is Serge Saxonov's approval rating as 10x Genomics' CEO?
25 employees have rated 10x Genomics CEO Serge Saxonov on Glassdoor.com . Serge Saxonov has an approval rating of 100% among 10x Genomics' employe...
Who are some of 10x Genomics' key competitors?
Some companies that are related to 10x Genomics include PerkinElmer (PKI) , Avantor (AVTR) , Waters (WAT) , Bio-Rad Laboratories (BIO.B) , Bio...
What is 10x genomics?
Is 10x genomics a big mover?
10x Genomics (Nasdaq: TXG), a life sciences leader focused on mastering biology to advance human health, today marked a major Asia Pacific (APAC) expansion with the grand opening celebration of its Singapore manufacturing facility and commercial hub.
Why does my stock price drop?
10x Genomics (TXG) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
When will Torex Gold Resources be released?
Earnings reports or recent company news can cause the stock price to drop . Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
What is Torex gold?
Torex Gold Resources (TXG-T) November 6, 2019. They've had two amazing quarters, but have had sociological and operational problems in western Mexico. Investors should have tight trailing stops to protect against any stock downside.
What does a high score mean on Torex?
Torex Gold Resources is a Canadian stock, trading under the symbol TXG-T on the Toronto Stock Exchange (TXG-CT). It is usually referred to as TSX:TXG or TXG-T
Where is ELG gold mined?
Stockchase rating for Torex Gold Resources is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.
Is Torex Gold in Mexico?
If looking to get into gold, this is a problem because everything has moved a fair bit. This company just declared commercial production at the ELG mine in Mexico. It is roughly 200,000 ounces at a cost of about $5.35. It goes to 350,000 ounces next year and the costs go down. It is the re-rating that he finds really attractive. Although it was moving up, it was lagging the group. It also did a 1 for 10 consolidation last week, which makes it more institutional. Thinks this could see $35 in one year.
Is Mexico a geopolitical risk?
Torex Gold Resources (TXG-T) April 3, 2018. Some of their Mexico properties have geo-politcal risk, though he likes Mexico as a whole to mine. They have cash and are getting this Mexico mine into production.
The problem was the company's worsening bottom line
Some of their Mexico properties have geo-politcal risk, though he likes Mexico as a whole to mine. They have cash and are getting this Mexico mine into production. They just had an EPS miss. This could be a buying opportunity.
By the numbers
Keith began writing for the Fool in 2012 and focuses primarily on healthcare investing topics. His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries. Follow @keithspeights
Behind the numbers
10x Genomics reported revenue in the fourth quarter of $112.2 million, a 49% year-over-year jump. This result easily beat the average analyst estimate of $100.4 million.
Looking ahead
10x Genomics' impressive revenue growth stemmed mainly from increased sales of consumables used with its single-cell genomic analysis instruments. That growth was itself driven by an expanding install base. By the end of 2020, 10x had sold a total of 2,412 Chromium instruments since launching the product in 2016.
How much did 10x lose in the first quarter?
10x Genomics expects full-year 2021 revenue of between $480 million and $500 million. The midpoint of this range represents year-over-year growth of 64%.
What is the gross margin of 10x?
In the prior-year period, 10x posted a GAAP net loss of $21.1 million, or $0.22 per share. The consensus Wall Street estimate projected a Q1 net loss of $0.27 per share.
How much will 10x generate in 2021?
10x's gross margin rose to 84% in the first quarter of 2021 from 79% in the prior-year period. This solid increase stemmed primarily from lower accrued royalties connected to an ongoing legal dispute.
Who is the CEO of 10x?
10x Genomics maintained its full-year 2021 revenue guidance of between $480 million and $500 million. This range reflects year-over-year growth of between 61% and 67%. The midpoint of the range is a little short of the consensus Wall Street revenue estimate of $495 million.
Is 10x genomics hot?
10x Genomics CEO Serge Saxonov said, "We had a solid start to the year highlighted by strong growth across the business and the incredible response to the innovation revealed at our inaugural Xperience event." That strong growth was primarily due to higher consumables revenue.
What Happened With Airline Stocks
10x Genomics ( NASDAQ:TXG) has been sizzling hot for much of 2021 so far. It hasn't hurt that Cathie Wood has been busy scooping up shares of the genomics company for her ARK Innovation ETF.
Why It Matters
Stock markets around the world are plunging today on news that a potentially more deadly variant of Covid-19 has emerged in South Africa. As the World Health Organization (WHO) convenes an emergency meeting in Geneva, Switzerland to discuss and examine the new variant, markets in Europe had their worst session in more than year.